By Fineline Cube Eli Lilly and Company (NYSE: LLY) has agreed to acquire Kelonia Therapeutics, a clinical-stage biotechnology firm pioneering in vivo gene delivery, in a deal valued at $7 billion. The transaction includes an upfront payment of $3.25 billion and up to $3.75 billion in milestone payments tied to clinical, regulatory, and commercial achievements. The acquisition—expected to close in H2 2026—gives Lilly full control of KLN-1010, a potentially transformative single-dose intravenous gene therapy for relapsed/refractory multiple myeloma.
Deal Structure & Strategic Rationale
| Component | Detail |
|---|---|
| Total Value | Up to $7 billion ($3.25B upfront + $3.75B milestones) |
| Target Asset | KLN-1010 – in vivo-generated anti-BCMA CAR-T therapy |
| Mechanism | Single IV infusion delivers genetic payload to generate functional CAR-T cells inside the body, eliminating need for ex vivo manufacturing |
| Key Advantages | – No leukapheresis or cell processing – No preconditioning chemotherapy – Potential for outpatient administration |
| Clinical Validation | Early data presented at ASH 2025 Plenary Session showed durable responses and favorable tolerability in heavily pretreated patients |
Multiple myeloma affects over 160,000 patients globally, with most eventually relapsing after standard therapies. Current ex vivo CAR-T products (e.g., Abecma, Carvykti) require complex logistics, weeks-long manufacturing, and toxic lymphodepletion—barriers KLN-1010 aims to overcome.
Technology Disruption Potential
Kelonia’s platform represents a paradigm shift in cell therapy:
- Manufacturing Simplified: Moves from centralized GMP facilities to scalable biologics production
- Access Expanded: Could enable treatment in community hospitals and emerging markets
- Cost Reduced: Eliminates >$500,000 per-patient manufacturing burden associated with autologous CAR-T
Lilly, already active in oncology with Retevmo and Jaypirca, gains a first-in-class in vivo CAR-T asset that complements its growing hematology pipeline and aligns with its strategy to lead in next-generation modalities.
Competitive Landscape
While companies like Sana Biotechnology, Capstan Therapeutics, and Takeda are exploring in vivo cell engineering, KLN-1010 is among the most clinically advanced, with human proof-of-concept already demonstrated. The ASH 2025 data showed deep and durable responses without cytokine release syndrome (CRS) ≥ Grade 3—a significant safety differentiator.
Post-acquisition, Lilly plans to accelerate global development, including pivotal trials and potential Breakthrough Therapy Designation discussions with the FDA.
Forward‑Looking Statements
This brief contains forward-looking information regarding acquisition timing, clinical development, and strategic benefits. Actual outcomes may differ due to regulatory reviews, trial results, and integration execution.-Fineline Info & Tech